Brainsway (BWAY)
NASDAQ:BWAY
Want to see BWAY full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.05Last Year’s EPS
0.03Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong operational execution and solid financial momentum: 35% revenue growth, 11th consecutive profitable quarter, substantial increases in net income and adjusted EBITDA, meaningful unit shipments (117 systems, +44% YoY), and expanding remaining performance obligations ($75M, +25% YoY). Management also presented attractive clinical advances (SWIFT results: ~70% reduction in clinic visits; 88% response, 78% remission) and clear strategic initiatives (Neurolief investment, minority stakes in provider networks, positive VA pricing). Key risks noted include higher operating expenses due to growth investments, reliance on payer adoption and FDA timing for new indications and protocols, and ongoing investments that increase near-term capital deployment. Overall, positives materially outweigh the challenges, with strong guidance for continued growth but some execution and reimbursement risks to monitor.Company Guidance
Strong Revenue Growth
Revenue increased 35% year-over-year to $15.5 million in Q1 2026 from $11.5 million in Q1 2025, driven by core business execution and expanded market penetration.
Repeat Profitability and Margin Expansion
Company reported its 11th consecutive quarter of profitability: net income rose to $2.3 million (more than 100% increase from $1.1 million prior year) and adjusted EBITDA increased 119% to $2.8 million (from $1.3 million). Gross profit was $11.6 million, up 35% year-over-year.
Unit Shipment and Installed Base Expansion
Shipped 117 Deep TMS systems in the quarter (up 44% year-over-year), bringing the total installed base to approximately 1,820 systems.
Growing Visibility into Future Revenue (RPO)
Remaining performance obligations (RPO) increased to $75 million as of March 31, 2026, a 25% year-over-year increase (from approximately $60 million), reflecting multiyear long-term contracts and recurring revenue traction.
SWIFT Protocol—Clinical and Payer Momentum
SWIFT 6-day acute-phase protocol validated in a peer-reviewed journal as reducing acute-phase clinic visits by ~70% while maintaining efficacy; reported clinical results of 88% response and 78% remission with the 6-day protocol. Early payer traction noted, with management expecting SWIFT coverage to reach ~40–50 million covered lives by year-end and early coverage policies issued by two large payers.
Regulatory and Clinical Pipeline Progress
Preparing FDA submission for PTSD symptoms in MDD patients with expectation of a response within the typical 90-day review window and potential clearance before year-end; multicenter patient recruitment underway for Deep TMS in alcohol use disorder.
Strategic Investments and Commercial Partnerships
Progress on minority equity investments in five mental health networks plus a new initial $1.5M (up to $3M total) strategic equity agreement with Hopemark; these MSO investments serve as commercial channels and growth catalysts.
Investment in Neurolief (ProlivRx) to Expand TAM
Convertible loan investment in Neurolief totaled $11 million (additional $6 million milestone loan completed in March bringing total to $11M) with a potential third tranche up to $5M. ProlivRx secured VA federal supply schedule and approved pricing at $11,800 per unit, supporting commercial roll-out for a complementary at-home neuromodulation offering.
Healthy Balance Sheet and Cash Generation
Reported cash and cash equivalents of $58.9 million, debt-free capital structure, positive operating cash flow in Q1, and approx. $9 million of strategic investments deployed in Q1 while preserving financial flexibility.
Full-Year Guidance with Strong Growth Expected
Management reiterated full-year 2026 revenue guidance of $66M–$68M (implying 27%–30% growth year-over-year), operating income target of 13%–14% of revenue, and adjusted EBITDA guidance of $12M–$14M (projected growth of ~86%–100% vs. 2025).
BWAY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BWAY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $16.74 | $16.31 | -2.57% |
Mar 11, 2026 | $12.71 | $13.77 | +8.34% |
Nov 11, 2025 | $8.06 | $7.59 | -5.83% |
Aug 13, 2025 | $6.09 | $6.35 | +4.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Brainsway (BWAY) report earnings?
Brainsway (BWAY) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Brainsway (BWAY) earnings time?
Brainsway (BWAY) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BWAY EPS forecast?
BWAY EPS forecast for the fiscal quarter 2026 (Q2) is 0.05.